![]() |
New to the Huntington's Disease Lighthouse? |
||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Posted to the HDL: 01 Aug 2007 Jessica Young, BS
The study involves filling out one survey that takes about 30-40 minutes to complete. If you take part in the study, you will be reimbursed with a $5 gift card to Wal-Mart for your time. The survey asks about your communication about Huntington’s disease to family and close friends and also asks about your general thoughts and feelings about yourself and your life. In order to take part in the study, you must fulfill the following eligibility criteria:
There are two ways to take the survey:
|
Research focusing on the formation of aggregates caused by HD
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
Research related HD and it's general affect on the brain
Research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease.
Research focusing on gene therapy.
Research focusing on gene transcription.
General research related to HD
Research studying the genetics of Huntington's Disease
Research studying the Immune System and it's effect on the progression of HD
Research studying the brain tissue and research related to stem cells
18 Jul 2008
Participants needed for qualitative studies of JHD
The University of Iowa is recruiting participants for two important new studies. 9 Jun 2008
The Research Pipeline - taking drugs from the lab to the clinic
Here's an overview of some of the more promising potential treatments moving through the research pipeline. 12 Mar 2008
Phase III creatine trial
NCCAM and the Orphan Product Division of the FDA is funding a phase III clinical trial of medicinal grade creatine. 1 Oct 2007
ACR16 closer to Phase III clinical trials
Neurosearch applies for permission to start Phase III clinical trials of ACR16, a dopamine stabilizer, in Europe and the U.S. 30 Sep 2007
Research Study for those At Risk
Last call for participants in an At Risk study. 19 Aug 2007
Riluzole Found Ineffective for Huntington's Disease Patients
A Phase III clinical trial of the glutamate blocker riluzole failed to slow progression or improve symptoms in HD patients.
1 Aug 2007
Daniel P. Van Kammen, MD, Phd, to lead CHDI Huntington's Disease Clinical Development Effort
MRSSI, Inc. announced today that Daniel P. van Kammen MD, PhD has joined as Chief Medical Officer.
31 Jul 2007
HD Study for Those At Risk
John Hopkins University and the National Human Genome Research Institute are starting a new study for those at risk.
28 Jul 2007
HSG to Conduct a Phase 2 Study in Adults with Mild-to-Moderate Huntington Disease
HSG announces a Phase II study of Dimebon
5 Feb 2007
Miraxion Study Completed, Results Soon
Amarin Corp. and the HSG have completed a Phase III clinical trial of Miraxion which investigated whether the drug improves motor symptoms in HD.
All Updates for Clinical Trials | ||||||||||||||||||||||
| Disclaimer & Privacy
Policy | |
|